Search results for " Left Ventricular"

showing 10 items of 119 documents

The Amino-Terminal Domain of GRK5 Inhibits Cardiac Hypertrophy through the Regulation of Calcium-Calmodulin Dependent Transcription Factors.

2018

We have recently demonstrated that the amino-terminal domain of G protein coupled receptor kinase (GRK) type 5, (GRK5-NT) inhibits NFκB activity in cardiac cells leading to a significant amelioration of LVH. Since GRK5-NT is known to bind calmodulin, this study aimed to evaluate the functional role of GRK5-NT in the regulation of calcium-calmodulin-dependent transcription factors. We found that the overexpression of GRK5-NT in cardiomyoblasts significantly reduced the activation and the nuclear translocation of NFAT and its cofactor GATA-4 in response to phenylephrine (PE). These results were confirmed in vivo in spontaneously hypertensive rats (SHR), in which intramyocardial adenovirus-med…

0301 basic medicineG-Protein-Coupled Receptor Kinase 5MalecalmodulinMutantWistarPlasma protein binding030204 cardiovascular system & hematologyCatalysilcsh:ChemistryPhenylephrine0302 clinical medicineRats Inbred SHRMyocytes Cardiaclcsh:QH301-705.5SpectroscopybiologyChemistrycardiac hypertrophyNFATComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineLeft VentricularComputer Science ApplicationsCell biologycardiac hypertrophy; transcription factors; calmodulin; GRKGRKHypertrophy Left VentricularCardiacProtein BindingInbred SHRCalmodulinCalmodulin; Cardiac hypertrophy; GRK; Transcription factors; Animals; Binding Sites; Calmodulin; Cell Line; G-Protein-Coupled Receptor Kinase 5; GATA4 Transcription Factor; Hypertrophy Left Ventricular; Male; Myocytes Cardiac; NFATC Transcription Factors; Phenylephrine; Protein Binding; Rats; Rats Inbred SHR; Rats Wistar; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryCatalysisArticleCell LineInorganic Chemistry03 medical and health sciencesG-Protein-Coupled Receptor Kinase 5transcription factorsAnimalsPhysical and Theoretical ChemistryRats WistarTranscription factorMolecular BiologyG protein-coupled receptor kinaseMyocytesBinding SitesNFATC Transcription FactorsOrganic ChemistryHypertrophyNFATC Transcription FactorsGATA4 Transcription FactorRats030104 developmental biologylcsh:Biology (General)lcsh:QD1-999biology.proteinTranscription factorInternational journal of molecular sciences
researchProduct

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct

Hemostatic function in young subjects with central obesity: relationship with left ventricular function.

1995

This study was designed to evaluate coagulation and fibrinolysis activity and their relationship with left ventricular function in young obese subjects with central fat distribution. We assessed coagulation and fibrinolysis activity by evaluation of factor VII activity, fibrinogen and plasminogen, plasminogen activator inhibitor (PAI), and tissue plasminogen activator antigen basally (tPA1) and after venous occlusion (tPA2). These measures were evaluated in young (< 40 years) obese subjects with central fat distribution (n = 19) and in comparable lean subjects (n = 20). Blood glucose, triglycerides, total and high-density lipoprotein (HDL) cholesterol, apolipoprotein (apo) A1 and apo B, fas…

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenVentricular Function LeftSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundEndocrinologyWaist–hip ratioInternal medicineFibrinolysismedicineHumansInsulinObesityHemostatic functionBlood CoagulationApolipoproteins ATriglyceridesApolipoproteins BHemostasisbiologybusiness.industryCholesterolCholesterol HDLFibrinogenCentral obesity Hemostatic function left ventricular functionPlasminogenFactor VIISettore MED/11 - Malattie Dell'Apparato CardiovascolarePlasminogen InactivatorsEndocrinologychemistrybiology.proteinBody ConstitutionRegression AnalysisFemalebusinessPlasminogen activatormedicine.drugLipoproteinMetabolism: clinical and experimental
researchProduct

Supraventricular arrhythmias in noncompaction of left ventricle: Is this a frequent complication?

2008

Background: Isolated left ventricular noncompaction is the result of incomplete myocardial morphogenesis, leading to persistence of the embryonic myocardium. The condition is recognised by an excessively prominent trabecular meshwork and deep intertrabecular recesses of the left ventricle. Whether these intertrabecular recesses are a favorable substrate for supraventricular arrhythmias is unclear, even if the incidence of chronic heart failure seems to be high. Results: We evaluated a continuous series of 238 patients affected by noncompaction. In 4 cases the patients reported palpitations and in 4 an episode of syncope. Periodic holter monitoring was performed every 6 months for 4 years. O…

AdultHeart Defects CongenitalMaleRegistriemedicine.medical_specialtyIsolated left ventricular noncompactionSupraventricular arrhythmiasPalpitation syncopeElectrocardiographyRisk FactorsRetrospective StudieInternal medicinemedicinePalpitationsTachycardia SupraventricularHumansRegistriescardiovascular diseasesRetrospective StudiesAgedAged 80 and overSupraventricular arrhythmiabusiness.industryIsolated left ventricular noncompaction; Supraventricular arrhythmias; Atrial fibrillation; Palpitation syncopeRisk FactorAtrial fibrillationMiddle Agedmedicine.diseaseAtrial fibrillationSupraventricular arrhythmiaSurgerymedicine.anatomical_structureItalyVentricleHeart failureCirculatory systemCardiologycardiovascular systemLeft ventricular noncompactionFemaleSupraventricular tachycardiamedicine.symptombusinessCardiology and Cardiovascular MedicineHuman
researchProduct

Ventricular tachycardia in non-compaction of left ventricle: Is this a frequent complication?

2007

Background: Isolated left ventricular non-compaction is the result of incomplete myocardial morphogenesis, leading to persistence of the embryonic myocardium. The condition is recognized by an excessively prominent trabecular meshwork and deep intertrabecular recesses of the left ventricle. Whether these intertrabecular recesses are a favorable substrate for ventricular arrhythmias is unclear. Some reports have found that the fatal ventricular arrhythmias may occur in approximately half of the patients. In this report we investigated about this association. Methods and Results: In total we evaluated a continuous series of 238 patients affected by non-compaction. Periodic Holter monitoring w…

AdultHeart Defects CongenitalMalemedicine.medical_specialtyVentricular tachycardiaElectrocardiographyVentricular arrhythmiasIsolated left ventricular non-compaction; Malignant; Ventricular arrhythmias; Ventricular tachycardiaRisk FactorsInternal medicinemedicineHumansRegistriesisolated left ventricular non-compaction ventricular arrhythmias ventricular tachycardia malignantcardiovascular diseasesRisk factorRetrospective StudiesMALIGNANCYIsolated left ventricular non-compactionMalignantbusiness.industryVentricular tachycardiaGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureItalyVentricleAnesthesiaChild PreschoolVentricular fibrillationCardiologyTachycardia Ventricularcardiovascular systemFemaleTrabecular meshworkCardiology and Cardiovascular MedicinebusinessComplicationHolter monitoringVENTRICULAR ARRHYTHMIAS.
researchProduct

Cardiac involvement in Friedreich's ataxia: our experience.

2009

AdultMaleAdolescentIncidenceFriedreich's ataxiaMiddle AgedAntioxidantsSampling StudiesFriedreich AtaxiaPrevalenceHumansFemaleHypertrophy Left VentricularSicilyAntihypertensive AgentsFollow-Up StudiesRetrospective Studies
researchProduct

Association between reduced lymphocyte beta-adrenergic receptors and left ventricular dysfunction in young obese subjects

1994

This study was designed to evaluate total (t) and surface (s) beta-adrenergic receptors (BAR) density and their relationships with left ventricular function in young obese subjects. BAR density, plasma insulin, catecholamines and left ventricular function were evaluated in 27 young obese subjects (BMI30.5 kg/m2 for males and27.3 kg/m2 for females) without other risk factors for cardiovascular diseases (smoking, hypertension, diabetes and lipid abnormalities) and in 20 lean controls (BMI25 kg/m2 for males and24.7 kg/m2 for females). Both groups were matched for gender, age and body height. BAR density was evaluated according to Böyum and De Blasi methods. Plasma catecholamines by high perfus…

AdultMaleAgingSettore MED/09 - Medicina InternaRadioimmunoassayPeripheral obesity Central Obesity lymphocyte beta adrenergic receptors left ventricular functionStroke VolumeSettore MED/11 - Malattie Dell'Apparato CardiovascolareVentricular Function LeftCatecholaminesEchocardiographyReceptors Adrenergic betaHumansInsulinRegression AnalysisFemaleLymphocytesObesityCardiac OutputRadionuclide AngiographyChromatography High Pressure Liquid
researchProduct

Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death

2013

Cardiac damage remains a major cause of mortality among patients with thalassemia major. The detection of a lower cardiac magnetic resonance T2* (CMR-T2*) signal has been suggested as a powerful predictor of the subsequent development of heart failure. However, the lack of worldwide availability of CMR-T2* facilities prevents its widespread use for follow-up evaluations of cardiac function in thalassemia major patients, warranting the need to assess the utility of other possible procedures. In this setting, the determination of left ventricular ejection fraction (LVEF) offers an accurate and reproducible method for heart function evaluation. These findings suggest a reduction in LVEF≥7%, ov…

AdultMaleCardiac function curvemedicine.medical_specialtyHeart diseaseThalassemiaThalassemia major Left ventricular ejection fraction (LVEF) Chelation Echocardiography Cardiac magnetic resonance T2*Young AdultInternal medicinemedicineHumansMolecular BiologySurvival analysisModels StatisticalEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeCell BiologyHematologyStroke volumemedicine.diseaseClinical trialDeath Sudden CardiacROC CurveEchocardiographyHeart failurecardiovascular systemCardiologyMolecular MedicineFemalebusinessBlood Cells, Molecules, and Diseases
researchProduct

Rapid left ventricular filling in untreated hypertensive subjects with or without left ventricular hypertrophy

1992

In this study, independent contribution of age, HR, BMI, casual and ambulatory blood pressure, LVM and LVEF in evaluating diastolic filling have been investigated in 34 never-treated hypertensive patients and in 15 healthy normotensive subjects. All the subjects were free from coronary artery disease, valvular disease, heart failure, renal disease and psychiatric problems. All the hypertensive subjects (never treated) were subgrouped according to presence or absence of LVH. The PFR decreased significantly and tPFR increased significantly in hypertensive patients in comparison with normotensive subjects and they did not change in the presence vs absence of LVH. The PFR was inversely correlat…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAmbulatory blood pressureSettore MED/09 - Medicina InternaDiastoleBlood PressureCritical Care and Intensive Care MedicineLeft ventricular hypertrophyVentricular Function LeftBlood Pressure Echocardiography Female Humans Hypertension/complications Hypertension/physiopathology* Hypertension/radionuclide imaging Hypertension/ultrasonography Hypertrophy Left Ventricular/complications Hypertrophy Left Ventricular/physiopathology* Hypertrophy Left Ventricular/radionuclide imaging Hypertrophy Left Ventricular/ultrasonography Male Middle Aged Radionuclide Angiography Ventricular Function Left*Coronary artery diseaseInternal medicinemedicineHumanscardiovascular diseasesRadionuclide AngiographyEjection fractionbusiness.industryMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMean blood pressureEchocardiographyHeart failureHypertensionCardiologyEnd-diastolic volumeFemaleHypertrophy Left VentricularCardiology and Cardiovascular Medicinebusiness
researchProduct

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

2011

The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by the absence of functional enzymes that contribute to the degradation of glycosaminoglycans (GAGs). The progressive systemic deposition of GAGs results in multi-organ system dysfunction that varies with the particular GAG deposited and the specific enzyme mutation(s) present. Cardiac involvement has been reported in all MPS syndromes and is a common and early feature, particularly for those with MPS I, II, and VI. Cardiac valve thickening, dysfunction (more severe for left-sided than for right-sided valves), and hypertrophy are commonly present; conduction abnormalities, coronary artery and other vascular in…

AdultMalemedicine.medical_specialtyAdolescentMucopolysaccharidosisClinical SciencesHeart Valve DiseasesReviewComorbidityCoronary Artery DiseaseDiseaseMuscle hypertrophyCoronary artery diseaseElectrocardiographyVentricular hypertrophyTachycardiaInternal medicineGeneticsmedicineHumansGenetics(clinical)Age of OnsetSinusChildPreschoolGenetics (clinical)GlycosaminoglycansGenetics & Hereditymedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyHypertrophyAortic Valve StenosisEnzyme replacement therapyMucopolysaccharidosesMiddle Agedmedicine.diseaseLeft VentricularCausalityTachycardia SinusEchocardiographyChild PreschoolAortic valve stenosisCardiologyHypertrophy Left VentricularFemalebusinessElectrocardiographyJournal of Inherited Metabolic Disease
researchProduct